ALPMF - Apellis spikes as Astellas posts long-term data for rival product
2023-09-19 09:29:45 ET
More on Astellas, Apellis, etc.
- Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market
- Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)
- Wells Fargo ups Apellis to overweight, stock climbs 8%
- Apellis rises 33% on eye drug Syfovre safety update
- Apellis falls as Astellas wins FDA nod for rival product
For further details see:
Apellis spikes as Astellas posts long-term data for rival product